About drug
Information about preparation
"Panavir" (application instructions)
Mechanism of "Panavir" action
Instruction to application
development
Preclinical development
Clinical development
Papillomavirus
Herpes
Ginecology and pregnacy
ncology
Cytomegalovirus
About company
Information about company
Contacts
Contacts

Home

   

What is Panavir

Print version Print version

Site dedicate to Russian broad-spectrum antiviral and immunomodulatory preparation. Preparation was developed by the company LLC "National Research Company" jointly with Research Institute of Physicochemical Medicine, Ministry of Health and Social Development of the Russian Federation, under the direction of the academician of RAMS Sergienko V.I.

Panavir - biologically active substance of Panavir is GG17 plant polysaccharide, relating tohexose glycoside class. It main dosage form intravenous solution 0,004% in 5 ml ampoules (single therapeutic dose). Additional dosage form: rectal suppositories, vaginal suppositories, gel for outward application. Preparation has original pharmacologic property, non-toxic in therapeutic dose (LD50 ~ 3000 therapeutic dose). It is successfully used where ordinary antiviral preparations are not effective or contraindicative or have unsatisfactorily effect: chronic tick-borne encephalitis, ophthalmoherpes, herpes zoster (shingles), cytomegalovirus, Epstein-Barr virus, Human papilloma virus. Now Panavir tests for treatment chronic hepatitis B and C.

Panavir - Russian broad-spectrum antiviral and immunomodulatory preparation.

Biologically active substance of Panavir is GG17 plant polysaccharide from Solanum tuberosum. GG17 is a high-molecular hexose glycoside with complex structure:

  • Glucose (38,5 %)
  • Galactose (14,5 %)
  • Rhamnose (9 %)
  • Mannose (2,5 %)
  • Xylose (1,5 %)
  • Uronic acid (3,5 %)

Panavir have original pharmacologic property, non-toxic in therapeutic dose (LD50 ~ 3000 therapeutic dose). Panavir is used successfully where ordinary antiviral preparations are not effective or contraindicative.

Panavir ATC Code J05 AX. Panavir increases nonspecific resistance for infection and improves interferon induction. Therapeutic dose of Panavir have good acceptability. Clinical trial shows absence of mutagenic, teratogenic, carcinogenic, allergenic, embryotoxic action.

Panavirs polysaccharides appear in serum in 5 minute after intravenous injections. Polysaccharides have been held by reticulo-endothelial system in liver and spleen. Excretions begin fast, after 20-30 min polysaccharides appear in urine and expired air.

Dosage form

Ampoule solution

(
application instructions)

Intravenous solution 0,04 mg/ml in 5 ml ampoules or vials. Intravenous solution 0,1 mg/ml in 2 ml ampoules or vials. Intravenous solution 0,2 mg/ml in 1 ml ampoules or vials.

Package contains 2 or 5 or 10 ampoules or vials in blister. Cardboard pack contains 1-2 packages with application instructions and ampule knife.

Gel for outward application

(application instructions)

Aluminium tube with lacquering in 3 gram, 5 gram, 10 gram and application instructions in cardboard pack.

At the registration stage

Vaginal suppositories

(application instructions)

Vaginal suppositories, weight 2.0g. Cardboard packs contains blister in 5 items with application instructions.

Rectal suppositories

(application instructions)

Rectal suppositories, weight 1.2g, Panavir 200 microgram. Cardboard packs contains blister in 5 items with application instructions.

Indications

  • Different body site Herpetic infection (including recidivicus genital herpes, shingles (herpes zoster), herpetic eye-lesion (ophthalmoherpes). Different body site primary and recurrent herpetic skin and mucous tunic lesions.
  • Secondary immunodeficiency state against the background infectious disease.
  • Cytomegalovirus infection with habitual noncarrying of pregnancy. It may be used in training pregnant women with chronic viral infection to labor.
  • Papilloma infection (anogenital wart) in complex therapy.

Panavir is used in therapy of tick-borne encephalitis for decrease viral load and neurological symptoms (anisoreflexia, reflex reduction, sickliness cerebral nerves output point) in complex therapy.

Side effects, contraindication

Panavir is counter-indicative at individual intolerance. Shouldnt apply to patients in case of allergy or intolerance to preparation component: glucose, mannose, rhamnose, galactose, xylose. Dont apply to patients with a severe kidneys or spleens pathology. Carefully apply at pregnancy and during lactation. Application during pregnancy is possible only in case when the prospective advantage for mother exceeds potential risk for fetus. If it is necessary applications during lactation needs stop chest feeding. The preparation have well tolerance, possible complications can be related with individual intolerance or hypersensitization to preparation components. At appearance any side effects stop introduction of substance and consult with the doctor.

Storage conditions

Rectal suppositories. Keep in a dry place, protected from light, out of the rich of children, at temperature from +2 to +10. Shelf life is 2 years.

Ampoules or vials. Keep in a dry place, protected from light, out of the rich of children, at temperature not higher than +25. Shelf life is 3 years. If solution has clouded it not allows using.

The preparation is strongly prohibited to apply after working life specified on packing. At turbidity of a solution the preparation is considered unfit for application.

Gel. Keep in a dry place, protected from light, out of the rich of children, at temperature not higher than +25. Shelf life is 2 years. Dont use at the end of shelf life.

Vaginal suppositories. Keep in a dry place, protected from light, out of the rich of children, at temperature from +2 to +10. Shelf life is 2 years.